COVID-19: Vaccine Receives Approval in Germany

BERLIN — The German biotech company BioNTech will become the first European business to proceed with clinical trials of a Covid-19 vaccine, after receiving regulatory approval for accelerated testing. 

The Mainz-based company, which has never produced a market-ready product, has been working on a vaccine since January and has tested an early version on mice. It will now test four variants of a prototype on 200 healthy volunteers aged between 18 and 55, with the aim of being able to manufacture a certified vaccine in less than a year. 

Prominent investors:

- $135m from Shanghai-based Fosun

- Bill & Melinda Gates Foundation

https://www.global-gathering.com/news/19185

>>8886054

Paul Ehrlich Institut: First Clinical Trial of a COVID-19 Vaccine Authorised in Germany

The vaccine candidate of the Biotechnology company BioNTech at Mainz is a so-called RNA vaccine, which contains the genetic information for the construction of the so-called spike protein of CoV-2 or parts thereof in the form of ribonucleic acid (RNA). In the authorised first part of the authorised clinical trial, 200 healthy volunteers aged between 18 and 55 years will be vaccinated in each case with one or more than one variants of the vaccine, each of which is slightly modified. After an observational waiting period, additional volunteers of the same age range will be vaccinated in the second part of the clinical trial. The additional inclusion of persons with an increased infection risk or an increased risk of a serious course of a COVID-19 disease is planned for the second part of the clinical trial, for which additional study data are required to be submitted in advance.

In the authorised part of the clinical trial, different variants of the RNA vaccine candidates are tested. In addition to their tolerability, their ability to create an immune response to SARS-CoV-2 after a specific amount of RNA (dose) is also tested (first dose finding). In this context, different RNA types and different lengths and modifications of the spike protein are tested, as well as the effect of a second vaccination.

https://www.pei.de/EN/newsroom/press-releases/year/2020/08-first-clinical-trial-sars-cov-2-germany.html

EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE

Can a memefag change the title of the song to "Where have all the genders gone"?

In the EU Clinical Trials Register, I only see two.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE